相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Steven Knapper et al.
BLOOD (2017)
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Gabriel Ghiaur et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia
Giorgia Battipaglia et al.
CANCER (2017)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Andrew M. Brunner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Does FLT3 Mutation Impact Survival After Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Abhinav Deol et al.
CANCER (2016)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
O. Lindblad et al.
ONCOGENE (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
Fangli Chen et al.
ONCOTARGET (2016)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation
A. Tschan-Plessl et al.
ANNALS OF HEMATOLOGY (2015)
Getting a handle on hereditary CEBPA mutations
Courtney D. DiNardo
BLOOD (2015)
FXa variants advance toward a therapy for bleeding
Jonas Emsley
BLOOD (2015)
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia
Hamid Ali Nagi Al-Jamal et al.
BMC CANCER (2015)
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia
Tapan Kadia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Walter Fiedler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
Brenda W. Cooper et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Melanie Janning et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes
Salvador Alonso et al.
ONCOTARGET (2015)
Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Julie A. Zorn et al.
PLOS ONE (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
Xiaochuan Yang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Weiguo Zhang et al.
CLINICAL CANCER RESEARCH (2014)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Isabel Ben-Batalla et al.
BLOOD (2013)
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
Il-Kyoo Park et al.
BLOOD (2013)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
Susanne Schnittger et al.
GENES CHROMOSOMES & CANCER (2012)
Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome
Baichun Yang et al.
JOURNAL OF APPLIED TOXICOLOGY (2012)
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Salut Brunet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
R. M. Stone et al.
LEUKEMIA (2012)
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A. S. Moore et al.
LEUKEMIA (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase
Amir T. Fathi et al.
LEUKEMIA RESEARCH (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
Amy E. DeZern et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
Manish Sharma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12
Kensuke Kojima et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia
Aref Al-Kali et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Gautam Borthakur et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch
Wei Ding et al.
BLOOD (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K. W. Pratz et al.
LEUKEMIA (2010)
The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro
Brian B. Hasinoff et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
Brian B. Hasinoff
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Jianbiao Zhou et al.
BLOOD (2009)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002
Jennifer F. Yamamoto et al.
CANCER CAUSES & CONTROL (2008)
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts
T. M. Kohl et al.
LEUKEMIA (2007)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Constitutively activated FLT3 phosphorylates BAD partially through Pim-1
Kyu-Tae Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL
M Adam et al.
CANCER RESEARCH (2006)
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)
K Bagrintseva et al.
BLOOD (2005)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
KT Kim et al.
BLOOD (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
M Levis et al.
BLOOD (2001)
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2001)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
分享论文
